WALVAX(300142.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
WALVAX
300142.SZ
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.
1.470 T
300142.SZMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
C
BiotechnologyIndustry
Industry Ranking26/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE3.39%C
    • Profit Margin11.91%B
    • Gross Margin68.47%A
  • Growth ScoreD
    • Revenue YoY-10.59%E
    • Net Profit YoY118.68%A
    • Total Assets YoY-22.53%E
    • Net Assets YoY-31.99%E
  • Cash ScoreC
    • Cash Flow Margin221.28%B
    • OCF YoY-10.59%E
  • Operating ScoreD
    • Turnover0.19D
  • Debt ScoreB
    • Gearing Ratio29.79%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The U.S. Centers for Disease Control and Prevention simplifies the childhood vaccination schedule

    AASTOCKS·
    SZ
    300142
    -1.20%
    SH
    688185
    -2.46%
    HK
    06185
    -3.48%
    AASTOCKS·
    SZ
    300142
    -1.20%
    SH
    688185
    -2.46%
    HK
    06185
    -3.48%

    According to reports, pharmaceutical companies will raise the prices of 350 drugs in the United States next year, with an average increase of 4%

    AASTOCKS·
    SZ
    300142
    -1.20%
    SH
    688185
    -2.46%
    HK
    06185
    -3.48%
    AASTOCKS·
    SZ
    300142
    -1.20%
    SH
    688185
    -2.46%
    HK
    06185
    -3.48%

    Morning Trend | Tonix Pharmaceuticals Holding experiences significant intraday volatility, is a rebound trend about to start?

    Technical Forecast·
    SZ
    300142
    -1.20%
    SH
    688185
    -2.46%
    HK
    06185
    -3.48%
    Technical Forecast·
    SZ
    300142
    -1.20%
    SH
    688185
    -2.46%
    HK
    06185
    -3.48%

    Sinovac: Signed a ten-year vaccine cooperation agreement with the Brazilian Ministry of Health, creating the largest international order for Chinese vaccines

    Wallstreetcn·
    SH
    688185
    -2.46%
    HK
    06185
    -3.48%
    SH
    603392
    -2.45%
    Wallstreetcn·
    SH
    688185
    -2.46%
    HK
    06185
    -3.48%
    SH
    603392
    -2.45%

    U.S. Department of Health and Human Services Kennedy discusses the measles, mumps, and rubella vaccine: studying the feasibility of Trump's request to split it into separate injections

    Zhitong·
    SZ
    300142
    -1.20%
    Zhitong·
    SZ
    300142
    -1.20%
    © 2026 Longbridge｜Disclaimer